Despite a recent boom in initial public offering (IPO) activity, there is a long-term trend of fewer companies listing – a problem for private investors looking to access some of the most exciting growth opportunities.
The reasons are clear. Technology makes running many businesses less capital-intensive, accessing capital has become cheaper and easier, and the reporting requirements that come with being listed are enough to put a number of firms off.
This may be more important than ever as we emerge from the pandemic. The speed of change of economies has accelerated and there is a significant amount of technological disruption to come. One particularly exciting area is the innovations gene sequencing will offer to medical science.